1 209

Cited 15 times in

Co-transplantation of bone marrow-derived mesenchymal stem cells and nanospheres containing FGF-2 improve cell survival and neurological function in the injured rat spinal cord

 Dong Ah Shin  ;  William A. Pennant  ;  Do Heum Yoon  ;  Yoon Ha  ;  Keung Nyun Kim 
 ACTA NEUROCHIRURGICA, Vol.156(2) : 297-303, 2014 
Journal Title
Issue Date
Animals ; Bone Marrow Cells/cytology* ; Cell Survival/drug effects ; Disease Models, Animal ; Fibroblast Growth Factor 2/pharmacology* ; Mesenchymal Stromal Cells/cytology* ; Nanospheres/administration & dosage* ; Nerve Regeneration/drug effects ; Nerve Regeneration/physiology ; Rats ; Rats, Sprague-Dawley ; Recovery of Function/drug effects ; Spinal Cord Injuries/surgery ; Spinal Cord Injuries/therapy*
Bone marrow ; Mesenchymal stem cells ; Nanosphere ; FGF-2 ; Spinal cord injury
BACKGROUND: Spinal cord injury (SCI) is a devastating and irreversible event, and much research using fibroblast growth factor-2 (FGF-2) has been performed to test its capacity to blunt the effects of SCI as well as to provide an environment conducive for SCI repair. METHODS: We tested how the in vitro release of FGF-2 from heparin-conjugated poly(L-lactide-co-glycolide) (PLGA)-conjugated nanospheres (HCPNs) affected the growth of human bone marrow-derived mesenchymal stem cells (hBMSCs), as well as the effects of their co-transplantation in an animal model of SCI. RESULTS: Our results showed that sustained, long-term release of FGF-2 from HCPNs significantly increased hBMSCs proliferation in vitro, and that their co-transplantation following rat SCI lead to increased functional improvement, a greater amount of hBMSCs surviving transplantation, and a greater density of neurofilament-positive cells in the injury epicenter. CONCLUSION: These results suggest a proliferative, protective, and neural inductive potential of FGF-2 for transplanted hBMSCs, as well as a possible role for sustained FGF-2 delivery along with hBMSCs transplantation in the injured spinal cord. Future studies will be required to ascertain the safety FGF-2-containing HCPNs before clinical application.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Keung Nyun(김긍년)
Shin, Dong Ah(신동아) ORCID logo https://orcid.org/0000-0002-5225-4083
Yoon, Do Heum(윤도흠) ORCID logo https://orcid.org/0000-0003-1452-5724
Ha, Yoon(하윤)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.